Loading
This study tests a PARP inhibitor; the registry reports that it is recruiting.
The registry lists NCT03990896 as recruiting, last updated 2026-05-06. Enrolment is 30 planned participants, an estimate. Interventions: Talazoparib. Primary measures include Median Progression Free Survival. No results are posted in the registry; this does not exclude separate publications.
Shares PARP, Breast cancer (all types).
Shares PARP, Breast cancer (all types).
Shares PARP, Breast cancer (all types).
Shares PARP, Breast cancer (all types).
Shares PARP, Breast cancer (all types).
Shares PARP, Breast cancer (all types).
Shares PARP, Breast cancer (all types).
Shares PARP, Breast cancer (all types).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/